Biofarma Positioning For Growth in Turkish Market
This article was originally published in PharmAsia News
Biofarma, one of the dynamic actors in the challenging Turkish pharmaceutical market, put up a strong performance in 2012–13 and its owners are now looking to benefit. So far, information on a likely share sale by one or both of the firm’s two investors has not been released, but Biofarma is looking forward to new opportunities and as sales and marketing director Gurhan Kaba told PharmAsia News in an exclusive interview, “Biofarma is a platform ready to grow.”
You may also be interested in...
GlaxoSmithKline PLC is rumored to be among three final bidders for Turkish generic drug maker Biofarma Pharmaceutical Industry Co. Inc. MNCs in Turkey are stepping up plans to establish a local manufacturing presence in Turkey to respond to continued price pressure, according to analysts
Turkey’s efforts to control rising rates of COVID-19 are compromising the ability of hospitals to pay their debts to medtech and pharmaceutical companies. The government has devised a payments plan, but there is catch.
The Turkish medtech industry’s ongoing hospital payments problems appeared likely to come back onto the government’s agenda, with the national economy recovering somewhat in late 2019. But COVID-19 dashed those hopes.